Hysteroscopic treatment of symptomatic adenomyoma
article
OA: gold
CC0
⤵ 4 in-corpus citations
Abstract
Hysterectomy has been the definitive treatment option for symptomatic adenomyosis and/or adenomyoma when medical or other conservative treatments fail to control the symptoms. Conservative surgery has already developed as an alternative treatment because of patients’ increasing desire to preserve their uterus. This video demonstrates a novel hysteroscopic treatment of symptomatic adenomyoma for patients with no desire for fertility.
My notes (saved in your browser only)
Condition tags
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (2)
- The Role of Hysteroscopy in the Diagnosis and Treatment of Adenomyosis 2017
- Hysteroscopic excision of symptomatic myometrial adenomyosis: feasibility and effectiveness 2017
Cited by (4)
- Stepwise approach of hysteroscopic cytoreductive surgery for adenomyosis in patients with recurrent implantation failure 2024
- Postmenopausal giant uterine adenomyoma with adipose metaplasia: A case report and literature review 2024
- Current Trends of Alternatives to Hysterectomy in Adenomyosis: A Review Article 2023
- Modified laparoscopic uterine-sparing surgery combined with gonadotropin-releasing hormone agonist therapy for focal uterine adenomyosis 2022
References (5)
- Hysteroscopic excision of symptomatic myometrial adenomyosis: feasibility and effectiveness via openalex
- The Role of Hysteroscopy in the Diagnosis and Treatment of Adenomyosis via openalex
- W2033363713 via openalex
- W2081898822 via openalex
- W6658602003 via openalex
Cited by (4)
- Postmenopausal giant uterine adenomyoma with adipose metaplasia: A case report and literature review 2024
- Stepwise approach of hysteroscopic cytoreductive surgery for adenomyosis in patients with recurrent implantation failure 2024
- Current Trends of Alternatives to Hysterectomy in Adenomyosis: A Review Article 2023
- Modified laparoscopic uterine-sparing surgery combined with gonadotropin-releasing hormone agonist therapy for focal uterine adenomyosis 2022
Source provenance
- europepmc
- last seen: 2026-06-18T06:15:08.409253+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:22:41.077124+00:00
License: CC0
· commercial use OK